Investigation of the beta 2-agonist properties of dilevalol: metabolic effects of intravenous infusion.
We describe two studies which investigate the beta 2-agonist properties of dilevalol. We have previously demonstrated, by giving an infusion of terbutaline to human volunteers, that beta 2-stimulation causes a rise in plasma glucose and a fall in plasma potassium. These metabolic effects can be prevented by prior beta-blockade. We now show that infusion of dilevalol produces similar, but quantitatively smaller, metabolic effects at a dose which also produces clinically significant beta-blockade, as judged by a fall in exercise heart rate. This adds support to the claim that dilevalol is a non-selective beta-blocker with selective beta 2-agonist activity.
Kendall
M J
MJ
Department of Pharmacology, Medical School, University of Birmingham, UK.
Lewis
H M
HM
Haffner
C A
CA
Hughes
B A
BA
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D015444:Exercise; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007262:Infusions, Intravenous; D007741:Labetalol / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D010869:Pindolol / Q000494:pharmacology; D011188:Potassium / Q000097:blood; D012016:Reference Values; D013726:Terbutaline / Q000494:pharmacology
D001786:Blood Glucose; D010869:Pindolol; D013726:Terbutaline; D007741:Labetalol; D011188:Potassium